China Shenghuo Pharmaceutical Holdings, Inc. To Present at Brean Murray Carret & Co. Mainland China Investor Tour
Posted on: Wednesday, 2 April 2008, 09:01 CDT
KUNMING, China, April 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced that it will present at the upcoming Brean Murray Carret & Co. Mainland China Investor Tour to be held at Grand Hyatt Shanghai on April 4, 2008.
The Brean Murray Carret & Co. Mainland China Investor Tour is a five-day event featuring presentations from 67 U.S.-listed Chinese companies from a number of sectors, such as technology, healthcare, energy, industrial and consumer products.
Date: Friday, April 4, 2008 Time: 9:00 a.m. Beijing time Venue: The Grand Hyatt Shanghai, 88 Century Blvd., Jin Mao Tower, Shanghai
Participation in the Brean Murray Carret & Co. Mainland China Investor Tour is by invitation only. Further information can be found at http://www.breanmurraycarret.com/ .
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns twenty-eight SFDA (State Food and Drug Administration)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn/ .
For more information, please contact: China Shenghuo Pharmaceutical Holdings, Inc. Ms. Gao Qionghua, CFO Tel: +86-871-728-2608 Email: qionghua_kmsh@163.com CCG Elite Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com
China Shenghuo Pharmaceutical Holdings, Inc.
CONTACT: China Shenghuo Pharmaceutical Holdings, Inc. - Ms. Gao Qionghua,CFO, +86-871-728-2608, or qionghua_kmsh@163.com; or CCG Elite InvestorRelations - Crocker Coulson, President, +1-646-213-1915 (New York), orcrocker.coulson@ccgir.com
Web Site: http://www.shenghuo.com.cn/
Source: PRNewswire
Related Articles
- China Shenghuo Reports Unaudited Financial Results for the First Quarter of 2009
- China Shenghuo Reports Year 2008 Financial Results
- China Shenghuo Announces Management Expansion and Enhanced Internal Controls
- China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards
- China Shenghuo to Resume Trading on NYSE Alternext US LLC
- China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores
- China Shenghuo Pharmaceutical Holdings, Inc. To Present at Roth 2007 New York Conference
- China Shenghuo Pharmaceutical Holdings, Inc. To Ring Opening Bell at American Stock Exchange
- China Shenghuo Pharmaceutical Holdings, Inc. Announces Listing on American Stock Exchange and Closing of Public Offering
 |
 |
User Comments (0)
RSS Feeds